Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

NCI supports clinical development of StressGen's lead product

Oct. 7, 1999

York Medical to commence phase I/II trial of head and neck cancer therapy

Sep. 30, 1999

ImmunoGen exercises put option

Sep. 30, 1999

StressGen completes phase I trial of HspE7

Sep. 28, 1999

TriAb prolongs disease progression in breast cancer patients

Sep. 27, 1999

GM-CSF and MDX-H210 assessed in pilot trial in cancer patients

Sep. 24, 1999

FDA accepts IND for ImmunoGen's tumor-activated prodrug

Sep. 23, 1999

Kyowa Hakko begins clinical testing of MAb as melanoma Rx

Sep. 21, 1999

Genzyme Molecular Oncology reports preclinical results, collaboration for aaATIII

Sep. 21, 1999

Biomira updates development activites at recent healthcare conference

Sep. 17, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 4, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...